Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
Add more filters










Publication year range
1.
Gene ; 927: 148743, 2024 Jul 02.
Article in English | MEDLINE | ID: mdl-38964493

ABSTRACT

Fascin-1 (FSCN1) is recognized as an actin-binding protein, commonly exhibits up-regulation in breast cancer (BC) and is crucial for tumor invasion and metastasis. The existence of FSCN1 gene polymorphisms may raise the potential for developing BC, and there are still no studies focusing on the relationship between the FSCN1 rs2966447 variant and BC risk in Egyptian females. Thus, we investigated the serum fascin-1 levels in BC patients and the association between the FSCN1 rs2966447 variant with its serum levels and BC susceptibility. Genotyping was conducted in 153 treatment-naïve BC females with different stages and 144 apparent healthy females by TaqMan® allelic discrimination assay, whereas serum fascin-1 level quantification was employed by ELISA. The FSCN1 rs2966447 variant demonstrated a significant association with BC susceptibility under all utilized genetic models, cancer stages and estrogen receptor negativity. Also, BC females with AT and TT genotypes had higher serum fascin-1 levels and tumor size than those with the AA genotype. Moreover, serum fascin-1 levels were significantly elevated in the BC females, notably in those with advanced-stages. Furthermore, serum fascin-1 levels were markedly positively correlated with number of positive lymph nodes as well as tumor size. Collectively, these findings revealed that the FSCN1 rs2966447 variant may be regarded as a strong candidate for BC susceptibility. Also, this intronic variant is associated with increased serum fascin-1 levels and tumor size.

2.
Article in English | MEDLINE | ID: mdl-38916819

ABSTRACT

PURPOSE: Macrophage migration inhibitory factor (MIF) is an integral cytokine for the modulation of both innate and adaptive immunity and is involved in the pathogenesis of various cancers. However, conflicting findings on the relationship between MIF polymorphisms and breast cancer (BC) have been reported in earlier research. We investigated the clinical value of serum MIF levels and the association between MIF rs1049829 and rs755622 variants with their serum levels and propensity to develop BC. METHODS: A total of 133 treatment-naïve Egyptian BC females and 126 apparently healthy controls were matriculated in this case-control study. The serum MIF protein levels were quantified by ELISA, whereas the genotyping was executed utilizing the TaqMan® allelic discrimination assay. RESULTS: A significant increase in the serum MIF level in BC cases was observed in comparison to control subjects (P < 0.0001), with a diagnostic potential to discriminate BC with 92.5% sensitivity and 73.7% specificity at a cut-off value > 9.47 ng/mL. Besides, a significant difference in serum MIF level was observed in BC cases with progesterone receptor (PR) negativity compared to those with PR positivity (P = 0.046). Moreover, a significant association was depicted between the rs1049829 variant of MIF gene and the protective effect against BC meanwhile the rs755622 variant demonstrated no significant link with BC risk. CONCLUSIONS: This study revealed that serum MIF levels may be regarded as a promising serum tumor marker for BC. Also, the rs1049829 variant of the MIF gene is considered a protective candidate against BC.

3.
Indian Pediatr ; 61(6): 521-526, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38517003

ABSTRACT

OBJECTIVE: To detect the efficacy of neutrophil gelatinase-associated lipocalin (NGAL) in the early prediction of acute kidney injury (AKI) in children undergoing cardiopulmonary bypass (CPB). METHODS: A prospective observational study was conducted wherein 174 patients, aged 6 to 60 months, with congenital heart disease, undergoing CPB and who had a normal baseline renal function were enrolled. Plasma NGAL measurement was done preoperatively and serially at 2, 12, 24, 36, and 48 hours post-CPB initiation. Patients were classified into 2 groups according to the development of postoperative AKI. RESULTS: Plasma NGAL levels post-CPB were significantly higher in the AKI group compared to the non-AKI group with positive significant correlations between plasma NGAL level and severity of AKI. A rise in plasma NGAL of 500% from its preoperative basal level, when measured at 2 hours post-CPB initiation (NGAL 2-0 index), showed sensitivity and specificity of 83% and 64%, respectively (AUC = 0.667) and at 12 hours post-CPB initiation (NGAL 12-0 index) showed sensitivity and specificity of 66% and 64% respectively (AUC = 0.762). CONCLUSION: Plasma NGAL is a predictive biomarker for acute kidney injury after pediatric cardiac surgery. A 500% rise in plasma NGAL at 2 hours post-CPB initiation from its basal preoperative level (NGAL 2-0 index) is a precise, sensitive, and early predictor of AKI in children.


Subject(s)
Acute Kidney Injury , Biomarkers , Cardiopulmonary Bypass , Lipocalin-2 , Humans , Acute Kidney Injury/blood , Acute Kidney Injury/diagnosis , Acute Kidney Injury/etiology , Lipocalin-2/blood , Cardiopulmonary Bypass/adverse effects , Child, Preschool , Infant , Male , Female , Prospective Studies , Biomarkers/blood , Heart Defects, Congenital/surgery , Heart Defects, Congenital/blood , Sensitivity and Specificity , Postoperative Complications/blood , Postoperative Complications/diagnosis
4.
Pathol Res Pract ; 254: 155079, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38219494

ABSTRACT

Breast cancer (BC) is the most common type of cancer in women to be diagnosed, and it is also the second leading cause of cancer death in women globally. It is the disease that causes the most life years adjusted for disability lost among women, making it a serious worldwide health issue. Understanding and interpreting carcinogenesis and metastatic pathways is critical for curing malignancy. Fascin-1 was recognized as an actin-bundling protein with parallel, rigid bundles as a result of the cross-linking of F-actin microfilaments. Increasing levels of fascin-1 have been associated with bad prognostic profiles, aggressiveness of clinical courses, and poor survival outcomes in a variety of human malignancies. Cancer cells that overexpress fascin-1 have higher capabilities for proliferation, invasion, migration, and metastasis. Fascin-1 is being considered as a potential target for therapy as well as a potential biomarker for diagnostics in a variety of cancer types. This review aims to provide an overview of the FSCN1 gene and its protein structure, elucidate its physiological and pathological roles, and throw light on its involvement in the initiation, development, and chemotherapeutic resistance of BC.


Subject(s)
Breast Neoplasms , Female , Humans , Breast Neoplasms/genetics , Biomarkers , Prognosis , Cell Line, Tumor , Carrier Proteins , Microfilament Proteins/metabolism
5.
Pathol Res Pract ; 253: 155023, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38081104

ABSTRACT

Parkinson's disease (PD) is a debilitating neurological disorder characterized by the impairment of the motor system, resulting in symptoms such as resting tremor, cogwheel rigidity, bradykinesia, difficulty with gait, and postural instability. The occurrence of striatal dopamine insufficiency can be attributed to a notable decline in dopaminergic neurons inside the substantia nigra pars compacta. Additionally, the development of Lewy bodies serves as a pathological hallmark of PD. While current therapy approaches for PD aim to preserve dopaminergic neurons or replenish dopamine levels in the brain, it is important to acknowledge that achieving complete remission of the condition remains elusive. MicroRNAs (miRNAs, miR) are a class of small, non-coding ribonucleic acids involved in regulating gene expression at the post-transcriptional level. The miRNAs play a crucial part in the underlying pathogenic mechanisms of several neurodegenerative illnesses, including PD. The aim of this review is to explore the role of miRNAs in regulating genes associated with the onset and progression of PD, investigate the potential of miRNAs as a diagnostic tool, assess the effectiveness of targeting specific miRNAs as an alternative therapeutic strategy to impede disease advancement, and discuss the utilization of newly developed nanoparticles for delivering miRNAs as neurodegenerative therapies.


Subject(s)
MicroRNAs , Parkinson Disease , Humans , MicroRNAs/metabolism , Parkinson Disease/diagnosis , Parkinson Disease/genetics , Parkinson Disease/therapy , Dopamine/therapeutic use , Brain/pathology
6.
Pathol Res Pract ; 252: 154947, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37977032

ABSTRACT

Malignant pleural mesothelioma (MPM) is a highly invasive form of lung cancer that adversely affects the pleural and other linings of the lungs. MPM is a very aggressive tumor that often has an advanced stage at diagnosis and a bad prognosis (between 7 and 12 months). When people who have been exposed to asbestos experience pleural effusion and pain that is not explained, MPM should be suspected. After being diagnosed, most MPM patients have a one- to four-year life expectancy. The life expectancy is approximately six months without treatment. Despite the plethora of current molecular investigations, a definitive universal molecular signature has yet to be discovered as the causative factor for the pathogenesis of MPM. MicroRNAs (miRNAs) are known to play a crucial role in the regulation of gene expression at the posttranscriptional level. The association between the expression of these short, non-coding RNAs and several neoplasms, including MPM, has been observed. Although the incidence of MPM is very low, there has been a significant increase in research focused on miRNAs in the past few years. In addition, miRNAs have been found to have a role in various regulatory signaling pathways associated with MPM, such as the Notch signaling network, Wnt/ß-catenin, mutation of KRAS, JAK/STAT signaling circuit, protein kinase B (AKT), and Hedgehog signaling pathway. This study provides a comprehensive overview of the existing understanding of the roles of miRNAs in the underlying mechanisms of pathogenic symptoms in MPM, highlighting their potential as viable targets for therapeutic interventions.


Subject(s)
Lung Neoplasms , Mesothelioma, Malignant , Mesothelioma , MicroRNAs , Pleural Neoplasms , Humans , MicroRNAs/genetics , Mesothelioma/diagnosis , Pleural Neoplasms/pathology , Hedgehog Proteins , Lung Neoplasms/pathology , Signal Transduction/genetics
7.
Pathol Res Pract ; 252: 154949, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37992507

ABSTRACT

Oral cancer (OC) is the predominant type originating in the head and neck region. The incidence of OC is mostly associated with behavioral risk factors, including tobacco smoking and excessive alcohol intake. Additionally, there is a lower but still significant association with viral infections such as human papillomaviruses and Epstein-Barr viruses. Furthermore, it has been observed that heritable genetic variables are linked to the risk of OC, in addition to the previously mentioned acquired risk factors. The current absence of biomarkers for OC diagnosis contributes to the frequent occurrence of advanced-stage diagnoses among patients. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs, and circular RNAs, have been observed to exert a significant effect on the transcriptional control of target genes involved in cancer, either through direct or indirect mechanisms. miRNAs are a class of short ncRNAs that play a role in regulating gene expression by enabling mRNA degradation or translational repression at the post-transcriptional phase. miRNAs are known to play a fundamental role in the development of cancer and the regulation of oncogenic cell processes. Notch signaling, PTEN/Akt/mTOR axis, KRAS mutation, JAK/STAT signaling, P53, EGFR, and the VEGFs have all been linked to OC, and miRNAs have been shown to have a role in all of these. The dysregulation of miRNA has been identified in cases of OC and is linked with prognosis.


Subject(s)
MicroRNAs , Mouth Neoplasms , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , Mouth Neoplasms/genetics , Mouth Neoplasms/diagnosis , Signal Transduction/genetics , Gene Expression Regulation , Herpesvirus 4, Human/genetics , Gene Expression Regulation, Neoplastic
8.
Pathol Res Pract ; 251: 154872, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37820441

ABSTRACT

Women of reproductive age are frequently affected by the heterogeneous endocrine-metabolic conditions recognized as polycystic ovarian syndrome (PCOS). Moreover, FSH (Follicle-stimulating hormone), steroidogenesis, and LH (Luteinizing Hormone) are suppressed by the anti-Mullerian hormone, a good indicator of ovarian reserve, that is generated from granulosa cells. In the past ten years, vitamin D (VD) has attracted and maintained great interest in human health and biomedical research, particularly those about female reproductive-metabolic problems. Therefore, this study was designed to evaluate the correlation of VD and AMH with PCOS parameters in Egyptian women. Assessments were done on 35 control women and 45 PCOS sufferers. Utilizing the updated Rotterdam criteria, PCOS was identified. After recording anthropometric data, fasting serum levels of VD, follistatin (FST), insulin, FSH, LH, total testosterone (TT), sex hormone binding globulin (SHBG), as well as fasting plasma glucose (FPG), and the free androgen index (FAI) were measured in both groups. Compared to the control group, the PCOS group had a greater prevalence of hypovitaminosis D but serum levels of follistatin, LH, TT, AMH, insulin, and FPG, were considerably higher. Besides, there was a substantial inverse relationship between VD and the levels of follistatin, FPG, LH, TT, and AMH and a positive correlation with FSH in PCOS women's blood. This study revealed that hypovitaminosis D, elevated AMH, and FST may be regarded as alarming risk factors for PCOS in Egyptian women.


Subject(s)
Polycystic Ovary Syndrome , Vitamin D Deficiency , Female , Humans , Anti-Mullerian Hormone , Clinical Relevance , Egypt , Follicle Stimulating Hormone , Follistatin , Insulin , Obesity/complications , Testosterone , Vitamin D , Vitamin D Deficiency/complications
9.
Pathol Res Pract ; 250: 154817, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37713736

ABSTRACT

Malignant pleural mesothelioma (MPM) is a highly lethal form of pleural cancer characterized by a scarcity of effective therapeutic interventions, resulting in unfavorable prognoses for afflicted individuals. Besides, many patients experience substantial consequences from being diagnosed in advanced stages. The available diagnostic, prognostic, and therapeutic options for MPM are restricted in scope. MicroRNAs (miRNAs) are a subset of small, noncoding RNA molecules that exert significant regulatory influence over several cellular processes within cell biology. A wide range of miRNAs have atypical expression patterns in cancer, serving specific functions as either tumor suppressors or oncomiRs. This review aims to collate, epitomize, and analyze the latest scholarly investigations on miRNAs that are believed to be implicated in the dysregulation leading to MPM. miRNAs are also discussed concerning their potential clinical usefulness as diagnostic and prognostic biomarkers for MPM. The future holds promising prospects for enhancing diagnostic, prognostic, and therapeutic modalities for MPM, with miRNAs emerging as a potential trigger for such advancements.

10.
Pathol Res Pract ; 249: 154771, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37611429

ABSTRACT

Merkel cell carcinoma (MCC) is an uncommon invasive form of skin cancer that typically manifests as a nodule on the face, head, or neck that is flesh-colored or bluish-red in appearance. Rapid growth and metastasis are hallmarks of MCC. MCC has the second-greatest mortality rate among skin cancers after melanoma. Despite the recent cascade of molecular investigations, no universal molecular signature has been identified as responsible for MCC's pathogenesis. The microRNAs (miRNAs) play a critical role in the post-transcriptional regulation of gene expression. Variations in the expression of these short, non-coding RNAs have been associated with various malignancies, including MCC. Although the incidence of MCC is very low, a significant amount of study has focused on the interaction of miRNAs in MCC. As such, the current survey is a speedy intensive route revealing the potential involvement of miRNAs in the pathogenesis of MCC beyond their association with survival in MCC.


Subject(s)
Carcinoma, Merkel Cell , Melanoma , MicroRNAs , Skin Neoplasms , Humans , MicroRNAs/genetics , Carcinoma, Merkel Cell/genetics , Signal Transduction , Skin Neoplasms/genetics , Melanoma/genetics
11.
Pathol Res Pract ; 249: 154763, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37595447

ABSTRACT

Merkel cell carcinoma (MCC) is a rare, aggressive form of skin malignancy with a high recurrence commonly within two to three years of initial diagnosis. The incidence of MCC has nearly doubled in the past few decades. Options for diagnosing, assessing, and treating MCC are limited. MicroRNAs (miRNAs) are a class of small, non-coding RNA molecules that play an important role in controlling many different aspects of cell biology. Many miRNAs are aberrantly expressed in distinct types of cancer, with some serving as tumor suppressors and others as oncomiRs. Therefore, the future holds great promise for the utilization of miRNAs in enhancing diagnostic, prognostic, and therapeutic approaches for MCC. Accordingly, the goal of this article is to compile, summarize, and discuss the latest research on miRNAs in MCC, highlighting their potential clinical utility as diagnostic and prognostic biomarkers.


Subject(s)
Carcinoma, Merkel Cell , MicroRNAs , Skin Neoplasms , Humans , MicroRNAs/genetics , Carcinoma, Merkel Cell/diagnosis , Carcinoma, Merkel Cell/genetics , Prognosis , Skin Neoplasms/diagnosis , Skin Neoplasms/genetics
12.
Bioorg Chem ; 139: 106729, 2023 10.
Article in English | MEDLINE | ID: mdl-37467621

ABSTRACT

Inhibiting the CDK2/cyclin A2 enzyme has been validated in multiple clinical manifestations related to multiple types of cancer. Herein, novel series of pyrolo[2,3-c]pyrazole, pyrolo[2,3-c]isoaxazole and pyrolo[2,3-d]pyrimidine, pyrolo[3,2-c]pyridine & indole based analogs were designed, synthesized and biologically evaluated for their in vitro antiproliferative activity where the obtained results revealed that most of the newly synthesized compounds showed significant cytotoxic activity towards MCF-7 (breast cancer cell lines) and HepG-2 (hepatocellular carcinoma) with IC50 ranging from 3.20 µM to 10.05 µM & from 2.18 µM to 13.49 µM, respectively, compared to that of Sorafenib (IC50 9.76 & 13.19 µM, respectively). The in vitro inhibitory profile of the most promising compounds (9, 11, 14, 15, 16, 17 and 20) towards CDK2/CyclinA2 was evaluated. Compounds 14 & 15 exhibited potent inhibitory profile against CDK2 with (IC50 0.11 and 0.262 µM, respectively comparable to Sorafenib IC50 0.184 µM. Western blotting of 14 & 15 at MCF-7 cell line confirmed the diminishing activity on CDK2. Furthermore, both compounds exserted a significant cell cycle arrest and apoptosis. Moreover, the normal cell line cytotoxicity for both compounds revealed low cytotoxic results in normal cells rather than cancer cells. Molecular docking and dynamic simulation validated the potentiality of the newly synthesized compounds to have high binding affinity within CDK2 binding pocket. 3DQSAR pharmacophore, in-silico ADME/TOPKAT studies and drug-likeness showed proper pharmacokinetic properties and helped in structure requirements prediction. The obtained model and pattern of substitution could be used for further development of CDK2 inhibitors.


Subject(s)
Antineoplastic Agents , Molecular Dynamics Simulation , Humans , Structure-Activity Relationship , Molecular Structure , Sorafenib/pharmacology , Molecular Docking Simulation , Cell Proliferation , Drug Screening Assays, Antitumor , Antineoplastic Agents/chemistry , Pyrimidines/chemistry , Pyrazoles/chemistry , Protein Kinase Inhibitors , Cell Line, Tumor , Cyclin-Dependent Kinase 2
13.
Pathol Res Pract ; 248: 154690, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37473498

ABSTRACT

Adrenocortical carcinoma (ACC) is a highly malignant infrequent tumor with a dismal prognosis. microRNAs (miRNAs, miRs) are crucial in post-transcriptional gene expression regulation. Due to their ability to regulate multiple gene networks, miRNAs are central to the hallmarks of cancer, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, induction/access to the vasculature, activation of invasion and metastasis, reprogramming of cellular metabolism, and avoidance of immune destruction. ACC represents a singular form of neoplasia associated with aberrations in the expression of evolutionarily conserved short, non-coding RNAs. Recently, the role of miRNAs in ACC has been examined extensively despite the disease's rarity. Hence, the current review is a fast-intensive track elucidating the potential role of miRNAs in the pathogenesis of ACC besides their association with the survival of ACC.


Subject(s)
Adrenal Cortex Neoplasms , Adrenocortical Carcinoma , MicroRNAs , Humans , Adrenocortical Carcinoma/genetics , Adrenocortical Carcinoma/pathology , MicroRNAs/genetics , MicroRNAs/metabolism , Adrenal Cortex Neoplasms/genetics , Adrenal Cortex Neoplasms/pathology , Prognosis , Signal Transduction/genetics
14.
Pharmaceuticals (Basel) ; 16(7)2023 Jul 06.
Article in English | MEDLINE | ID: mdl-37513878

ABSTRACT

Background: Histone deacetylase inhibitors (HDACIs) are a relatively new class of potential drugs for treating cancer. Aim: Discovery of new anticancer agents targeting HDAC. Methods: New uracil and thiouracil derivatives panels were designed and synthesized as HDAC inhibitors. The synthesized compounds were tested against MCF-7, HepG2, and HCT-116. HDAC1 and HDAC4 inhibitory activities of these compounds were tested. The most active member was tested for its potential against cell cycle, apoptosis, caspase-3, and caspase-8. Docking studies were carried out against HDAC1. Results: Compounds 5a, 5b, 5f, 5i, 5k, and 5m exhibited promising cytotoxic activities. HDAC1 and HDAC4 inhibitory activities of these compounds were tested. Regarding the HDAC1 inhibitory activity, compound 5m was the most potent member (IC50 = 0.05 µg/mL) compared to trichostatin A (IC50 = 0.0349 µg/mL). For HDAC4, compound 5m showed superior activity (IC50 = 2.83 µg/mL) than trichostatin A (IC50 = 3.349 µg/mL). Compound 5m showed a high potential to arrest the HCT116 cell cycle at the G0-G1 phase. In addition, it showed an almost 17 times apoptotic effect (37.59%) compared to the control cells (2.17%). Furthermore, Compound 5m showed significant increases in the levels of caspase-3 and caspase-8. Finally, the uracil and thiouracil derivatives showed accepted binding mods against HDAC. Conclusions: Compound 5m has potential anticancer activity targeting HDAC with a significant apoptotic effect.

15.
Future Med Chem ; 15(12): 1019-1035, 2023 06.
Article in English | MEDLINE | ID: mdl-37492951

ABSTRACT

Background: Histone deacetylase (HDAC) inhibitors have good contributions in cancer management. Aim: To introduce new active HDAC inhibitors. Methods: Design and synthesis of 16 thiouracil derivatives with deep biological and computational investigation. Results: Compounds 7a, 7c, 7d, 7e, 8a and 8f showed the highest antiproliferative effects against MCF7, HepG2 and HCT116 cell lines. Compound 7e exhibited the highest activities against HDAC1 and HDAC4. Compound 7e arrested the cell cycle of HCT116 cells at G0-G1 with significant apoptotic effect. In addition, treatment with compound 7e was associated with a significant increase in the levels of caspase-3 and caspase-8. The docking studies gave good insight about the binding patterns of the synthesized compounds against HDAC1. Conclusion: Compound 7e has a promising anticancer activity targeting HDAC.


Subject(s)
Antineoplastic Agents , Cell Line, Tumor , Antineoplastic Agents/chemistry , Histone Deacetylase Inhibitors/chemistry , Structure-Activity Relationship , Cell Proliferation , Drug Design , Apoptosis , Molecular Docking Simulation , Drug Screening Assays, Antitumor
16.
Pathol Res Pract ; 248: 154665, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37418996

ABSTRACT

Adrenocortical carcinoma (ACC) is an uncommon aggressive endocrine malignancy that is nonetheless associated with significant mortality and morbidity rates because of endocrine and oncological consequences. Recent genome-wide investigations of ACC have advanced our understanding of the disease, but substantial obstacles remain to overcome regarding diagnosis and prognosis. MicroRNAs (miRNAs, miRs) play a crucial role in the development and metastasis of a wide range of carcinomas by regulating the expression of their target genes through various mechanisms causing translational repression or messenger RNA (mRNA) degradation. Along with miRNAs in the adrenocortical cancerous tissue, circulating miRNAs are considered barely invasive diagnostic or prognostic biomarkers of ACC. miRNAs may serve as treatment targets that expand the rather-limited therapeutic repertoire in the field of ACC. Patients with advanced ACC still have a poor prognosis when using the available treatments, despite a substantial improvement in understanding of the illness over the previous few decades. Accordingly, in this review, we provide a crucial overview of the recent studies in ACC-associated miRNAs regarding their diagnostic, prognostic, and potential therapeutic relevance.


Subject(s)
Adrenal Cortex Neoplasms , Adrenocortical Carcinoma , MicroRNAs , Humans , Adrenocortical Carcinoma/diagnosis , Adrenocortical Carcinoma/genetics , MicroRNAs/genetics , MicroRNAs/metabolism , Adrenal Cortex Neoplasms/diagnosis , Adrenal Cortex Neoplasms/genetics , Prognosis , Drug Resistance
17.
Pathol Res Pract ; 247: 154584, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37267724

ABSTRACT

Salivary gland cancer (SGC) is immensely heterogeneous, both in terms of its physical manifestation and its aggressiveness. Developing a novel diagnostic and prognostic detection method based on the noninvasive profiling of microribonucleic acids (miRs) could be a goal for the clinical management of these specific malignancies, sparing the patients' valuable time. miRs are promising candidates as prognostic biomarkers and therapeutic targets or factors that can advance the therapy of SGC due to their ability to posttranscriptionally regulate the expression of various genes involved in cell proliferation, differentiation, cell cycle, apoptosis, invasion, and angiogenesis. Depending on their biological function, many miRs may contribute to the development of SGC. Therefore, this article serves as an accelerated study guide for SGC and the biogenesis of miRs. Here, we shall list the miRs whose function in SGC pathogenesis has recently been determined with an emphasis on their potential applications as therapeutic targets. We will also offer a synopsis of the current state of knowledge about oncogenic and tumor suppressor miRs in relation to SGC.


Subject(s)
MicroRNAs , Salivary Gland Neoplasms , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , Salivary Gland Neoplasms/pathology , Genes, Tumor Suppressor , Prognosis , Signal Transduction/genetics
18.
Pathol Res Pract ; 248: 154590, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37295259

ABSTRACT

Cancer of the salivary glands is one of the five major types of head and neck cancer. Due to radioresistance and a strong propensity for metastasis, the survival rate for nonresectable malignant tumors is dismal. Hence, more research is needed on salivary cancer's pathophysiology, particularly at the molecular level. The microRNAs (miRNAs) are a type of noncoding RNA that controls as many as 30% of all genes that code for proteins at the posttranscriptional level. Signature miRNA expression profiles have been established in several cancer types, suggesting a role for miRNAs in the incidence and progression of human malignancies. Salivary cancer tissues were shown to have significantly aberrant levels of miRNAs compared to normal salivary gland tissues, supporting the hypothesis that miRNAs play a crucial role in the carcinogenesis of salivary gland cancer (SGC). Besides, several SGC research articles reported potential biomarkers and therapeutic targets for the miRNA-based treatment of this malignancy. In this review, we will explore the regulatory impact of miRNAs on the processes underlying the molecular pathology of SGC and provide an up-to-date summary of the literature on miRNAs that impacted this malignancy. We will eventually share information about their possible use as diagnostic, prognostic, and therapeutic biomarkers in SGC.


Subject(s)
Head and Neck Neoplasms , MicroRNAs , Salivary Gland Neoplasms , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , Salivary Gland Neoplasms/diagnosis , Salivary Gland Neoplasms/genetics , Salivary Gland Neoplasms/metabolism , Salivary Glands/pathology , Head and Neck Neoplasms/pathology , Drug Resistance , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Gene Expression Regulation, Neoplastic/genetics
19.
Pathol Res Pract ; 248: 154613, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37327567

ABSTRACT

MicroRNAs (miRNAs; miRs) are small non-coding ribonucleic acids sequences vital in regulating gene expression. They are significant in many biological and pathological processes and are even detectable in various body fluids such as serum, plasma, and urine. Research has demonstrated that the irregularity of miRNA in multiplying cardiac cells is linked to developmental deformities in the heart's structure. It has also shown that miRNAs are crucial in diagnosing and progressing several cardiovascular diseases (CVDs). The review covers the function of miRNAs in the pathophysiology of CVD. Additionally, the review provides an overview of the potential role of miRNAs as disease-specific diagnostic and prognostic biomarkers for human CVD, as well as their biological implications in CVD.

20.
Pathol Res Pract ; 248: 154624, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37348290

ABSTRACT

For the past two decades since their discovery, scientists have linked microRNAs (miRNAs) to posttranscriptional regulation of gene expression in critical cardiac physiological and pathological processes. Multiple non-coding RNA species regulate cardiac muscle phenotypes to stabilize cardiac homeostasis. Different cardiac pathological conditions, including arrhythmia, myocardial infarction, and hypertrophy, are modulated by non-coding RNAs in response to stress or other pathological conditions. Besides, miRNAs are implicated in several modulatory signaling pathways of cardiovascular disorders including mitogen-activated protein kinase, nuclear factor kappa beta, protein kinase B (AKT), NOD-like receptor family pyrin domain-containing 3 (NLRP3), Jun N-terminal kinases (JNKs), Toll-like receptors (TLRs) and apoptotic protease-activating factor 1 (Apaf-1)/caspases. This review highlights the potential role of miRNAs as therapeutic targets and updates our understanding of their roles in the processes underlying pathogenic phenotypes of cardiac muscle.


Subject(s)
Cardiovascular Diseases , Heart Diseases , MicroRNAs , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , Cardiovascular Diseases/genetics , Signal Transduction , Gene Expression Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...